Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Times Interest Earned (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Times Interest Earned for 5 consecutive years, with -$151.25 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Times Interest Earned fell 38.06% year-over-year to -$151.25, compared with a TTM value of -$145.86 through Jun 2025, down 179.12%, and an annual FY2025 reading of -$203.41, down 50.93% over the prior year.
  • Times Interest Earned was -$151.25 for Q2 2025 at SAB Biotherapeutics, down from -$141.22 in the prior quarter.
  • Across five years, Times Interest Earned topped out at $132.85 in Q4 2023 and bottomed at -$191.46 in Q4 2021.
  • Average Times Interest Earned over 5 years is -$85.93, with a median of -$91.85 recorded in 2022.
  • The sharpest move saw Times Interest Earned crashed 960.35% in 2022, then skyrocketed 248.23% in 2023.
  • Year by year, Times Interest Earned stood at -$191.46 in 2021, then skyrocketed by 53.19% to -$89.62 in 2022, then soared by 248.23% to $132.85 in 2023, then plummeted by 206.3% to -$141.22 in 2024, then fell by 7.1% to -$151.25 in 2025.
  • Business Quant data shows Times Interest Earned for SABS at -$151.25 in Q2 2025, -$141.22 in Q4 2024, and -$144.93 in Q3 2024.